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PEMBANGUNAN DAN PENILAIAN FORMULASI-FORMULASI MATRIKS 
PELEPASAN TERKAWAL BAGI KETOPROFEN 
 
ABSTRAK 
 
Kajian ini dijalankan untuk menyiasat kesesuaian pelbagai polimer hidrofilik dan 
hidrofobik atau gabungan-gabungan mereka, sebagai bahan-bahan pembentuk 
matriks untuk pembangunan formulasi tablet pelepasan terkawal ketoprofen dengan 
prestasi in vitro dan in vivo yang setanding dengan sediaan tablet Apo-Keto SR
® 
yang sudah dipasarkan. Dengan ini, pelbagai formulasi pelepasan terkawal matriks 
tablet ketoprofen telah dibangunkan dengan menggunakan bahan-bahan polimer 
hidrofilik, hidrofobik yang berbeza serta campuran-campurannya. Kesemua 
formulasi telah disediakan dengan menggunakan kaedah pemampatan terus. Profil 
pelarutan in vitro formulasi-formulasi telah dibandingkan dengan produk rujukan 
tablet Apo-Keto SR
® 
yang boleh diperolehi secara komersial. Faktor kesamaan (f2), 
nilai-nilai antara formulasi ujian dan produk rujukan juga telah dikira untuk 
pemilihan formulasi yang optimum. Daripada kesemua formulasi matriks yang telah 
dikaji, tablet-tablet yang mengandungi 20% HPC (GXF) sebagai pembentuk matriks 
menunjukkan profil pelarutan yang setanding dengan rujukan. Nilai f2 antara tablet-
tablet rujukan dan tablet-tablet matriks dengan 20% HPC (GXF) ialah 78.0%, dan 
oleh itu telah dipilih untuk siasatan lanjut. Pelepasan drug dari rujukan dan formulasi 
matriks dengan 20% HPC (GXF) telah dikawal oleh kedua-dua mekanisme resapan 
dan hakisan seperti dalam persamaan Korsmeyer-Peppas. Tambahan pula, formulasi 
yang telah dioptimasikan didapati stabil untuk tempoh 12 bulan dalam simpanan 
pada 25ºC suhu bilik untuk stabiliti jangkamosa panjang. Satu kaedah UV HPLC 
telah dibangunkan dan disahkan untuk pengenalpastian ketoprofen dalam plasma 
manusia. Satu kajian in vivo kemudian dikendalikan dengan 6 sukarelawan manusia 
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yang sihat untuk membandingkan prestasi formulasi ujian itu dengan produk rujukan 
komersial. Kajian dikendalikan mengikut rekabentuk kajian dos tunggal, rambang,  
2-rawatan, 2-turutan, pindah silang 2-tempoh. Keputusan statistik menunjukkan 
bahawa tidak ada perbezaan signifikan antara parameter-parameter farmakokinetik 
Tmax, Cmax, dan AUC0-∞ produk rujukan dan formulasi ujian. Selang keyakinan 90% 
nilai-nilai purata untuk nisbah ujian/rujukan ialah 96.9-107.0% untuk AUC0-∞ dan 
99.6-104.6% untuk Cmax, masing-masing. Maka, kadar dan takat penyerapan 
formulasi ujian adalah setanding dengan produk rujukan. Secara kesimpulan, satu 
tablet pelepasan terkawal matriks ketoprofen yang stabil telah berjaya dibangunkan, 
yang mempamerkan profil pelarutan in vitro yang serupa serta prestasi in vivo 
setanding dengan tablet rujukan Apo-Keto SR
® 
yang telah dipasarkan. 
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DEVELOPMENT AND EVALUATION OF MATRIX CONTROLLED 
RELEASE FORMULATIONS OF KETOPROFEN 
 
 
ABSTRACT 
 
The present study was conducted to investigate the suitability of various hydrophilic 
and hydrophobic polymers or their combination, as matrix forming materials for the 
development of a controlled release tablet formulation of ketoprofen with in vitro 
and in vivo performance comparable to that of the marketed preparation Apo-Keto 
SR
® 
tablets. In this regard a number of matrix controlled release formulations of 
ketoprofen tablets were developed using different hydrophilic, hydrophobic and 
mixtures of both polymeric materials. All the formulations were prepared by direct 
compression method. Their in vitro dissolution profiles were compared to that of the 
commercially available reference product Apo-Keto SR
®
 tablet. Similarity factor (f2), 
values between test formulations and reference product were also calculated to select 
the optimum formulation. Out of all the matrix formulations studied, tablets 
containing 20% HPC (GXF) as matrix former showed comparable dissolution profile 
to that of the reference. The f2 value between reference and matrix tablets with 20% 
HPC (GXF) was 78.0%, and hence it was selected for further investigation. The drug 
release from reference and matrix with 20% HPC (GXF) formulation was governed 
by both diffusion and erosion (anomalous) mechanism as per Korsmeyer-Peppas 
equation. Moreover, the optimized formulation was found to be stable for a period of 
12 months upon storage at 25ºC of room temperature for a long term of stability. A  
HPLC UV method was developed and validated for the determination of ketoprofen 
in human plasma. An in vivo study was then conducted in 6 healthy human 
volunteers to compare the performance of the test formulation with the commercial 
reference product. The study was performed according to a single dose, randomized, 
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2-treatment, 2-sequence, 2-period crossover study design. The statistical results 
showed that there was no significant difference between pharmacokinetic parameters 
of Tmax, Cmax, and AUC0-∞ of reference product and test formulation. The 90% 
confidence intervals of the mean values for the test/reference ratios were             
96.9-107.0% for AUC0-∞ and 99.6-104.6% for Cmax, respectively. Hence, the rate and 
extent of absorption of test formulation were comparable to the reference product. In 
conclusion, a stable matrix controlled release tablets of ketoprofen was successfully 
developed, which exhibited similar in vitro dissolution profile as well as in vivo 
performance as that of marketed reference tablet of Apo-Keto SR
®
. 
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CHAPTER 1    INTRODUCTION 
 
 
 
 
1.1 Oral controlled release dosage forms 
 
The oral route is the most popular, convenient and traditionally preferred mode of 
drug administration because of its ease and convenience to the patients. Ideally, an 
oral dosage form should deliver the drug at a designated location, at a specified rate, 
for a specific period of time (Juliano, 1980; Szycher, 1991). Once the drug is 
administered orally, it dissolves in the gastro intestinal fluids and gets absorbed into 
the systemic circulation. Blood is usually the medium of transport for the absorbed 
drug, thus the ideal plasma concentration levels which produces optimal therapeutic 
activity must be obtained. However, the drug delivery targets could only be achieved 
in part through conventional dosage forms (Lee and Good, 1987). 
 
Conventional dosage forms are designed to release their content without delay for 
absorption so that maximal rate and extent of absorption can be achieved. Hence, 
wide fluctuations in peak and trough steady-state drug levels are frequently obtained 
with these products with multiple dose administration, particularly for drugs having 
short biological half-lifes (Roda et al., 2002). By increasing the frequency of dosing, 
it may be possible to reduce such undesirable fluctuations particularly with drugs of 
narrow therapeutic indices. However, this may lead to patient inconvenience and poor 
compliance. In order to overcome this problem, various sustained release 
formulations have been developed to improve the therapeutic performance of drugs, 
such as to increase pharmacological efficacy with reduced side effects (Pather et al., 
1998; Sanchez-Lafuente et al., 2002; Kramar et al., 2003).  
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In recent years, controlled release dosage forms have made great progress in terms of 
improving clinical efficacy and patient compliance (Reza et al., 2003). An ideal 
controlled release formulation should release its drug at a constant rate and provide 
constant drug levels in plasma with reduced fluctuation over a time period, such that 
the duration of its therapeutic effect is sustained.  
 
One of the first attempts in the formulation of oral controlled release dosage forms 
was made by the German dermatologist, Paul G. Unna in 1884, in which the pills 
were coated with a thin film of keratin that would not dissolve in acidic gastric fluid 
but instead, dissolve in the intestine. In this way, he was among the first to introduce 
the enteric coating technique (Helfand and Cowen, 1982). 
 
A commercial controlled release preparation, namely Dexedrine Spansule® capsule 
was among the first to be introduced to the market in 1945 by Smith, Kline and 
French Laboratories (SK & F). It employed a coating technique described by Blythe 
(1956; 1958a; 1958b). The preparation consisted of many small coated pellets, which 
in spite of the environment would release the therapeutic substance at controlled 
rates. In this method, nonpareil seeds were first coated with the drug and the obtained 
beads were further coated in coating pans by applying or spraying a mixture of lipid 
substances. The lipid substances used were glyceryl mono-, di-, and tristearate and 
carnauba wax dissolved in organic solvent. Finally, the coated pellets of 1 to 2 mm in 
diameter were mixed with non coated ones and delivered in a gelatin capsule called a 
spansule (Swintosky, 1963).  
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Saunders (1961) suggested that controlled release of ionic drugs could be obtained 
by binding them with ion-exchange resins. Swintosky (1963) introduced the first 
liquid preparation of controlled release dosage form for oral administration in 1959, 
which was an aqueous suspension of drug granules, 35 µm in diameter, coated by 
hydrogenated castor oil and ethyl cellulose. 
 
Matrix tablets called the Duretter® which was produced by compressing granules to 
form plastic matrices (Fryklof et al., 1959) were introduced in 1959 (British Patent 
No. 808014). Since then, various sustained release product have been introduced 
with their mechanism of release being described by such names as extended release, 
sustained action, prolonged action, long acting and extended action preparations 
(Gupta, 1999). Also, from then on, many sustained or modified release products have 
been introduced into the market. 
 
The design and formulation of the early sustained release products in the 1950s were 
not without problems. At this time, the science of biopharmaceutics and 
pharmacokinetics was still in its infancy. As a result, these early products were 
formulated with little or no consideration of the absorption and disposition 
characteristics of the drug in the body. Also, the lack of appropriately sensitive 
analytical techniques at that time presumably made evaluation of the blood levels 
impossible. Thus the efficacy of these formulations could only be assessed by 
pharmacological methods which were often unreliable or even inapplicable to the 
drug under test. As the fields of biopharmaceutics and pharmacokinetics were better 
developed, the shortcomings of these old products became evident. Some of these 
old products were eventually withdrawn and improvements were made in the newer 
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formulations. Towards the end of 1960’s, a new phrase, controlled drug delivery was 
introduced. This term was applied to those formulations in which the rate of 
dissolution of drug from the dosage forms was controlled. Such products have 
enhanced bioavailability, efficacy and safety (Banker, 1979; Banker and Anderson, 
1986; 1987; 1991; Banakar, 1991).  
 
Significant progress has been made in this area in the past two decades, and today, 
sustained release formulations have become an important product line of most major 
drug companies. A variety of techniques have been used in the formulation of these 
products but they all basically work on the same principle of slowing the rate of 
dissolution or release of the drug from the dosage form. In general, there are two sets 
of methods to achieve this objective (Lordi, 1986). The first set is based on 
modification of those physical and/or chemical properties of the drug that affect 
bioavailability. These include the use of complex formulation (example tannate 
complexes), ion-exchange resins to form drug adsorbates, and prodrug synthesis. The 
mechanism of sustained drug release is through decreased rate of dissolution of the 
altered drug and/or dissociation of the free drug into solution. In the case of 
prodrugs, a slow regeneration of the parent compound after absorption may provide 
an additional strategy for prolonging the drug action. A major advantage of this 
approach is that it operates independently from the dosage form. The resulting drug 
modifications can thus be formulated as liquid suspensions, capsule or tablet. 
However, these methods can only be applied to drug moieties containing the 
appropriate functional groups. 
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In contrast, the second sets of methods are based on modification of the drug release 
characteristics of the dosage form. Although products based on dosage form 
modification are of many designs and constructions, the mechanisms underlying the 
sustained release are few (Lee and Robinson, 1978). A drug with a slow dissolution 
rate is inherently sustained. For those drugs with rapid dissolution, embedding them 
within a slowly dissolving or erodible matrix provides a means of retarding the 
dissolution rate. Various lipid materials, waxes and other polymers have been found 
to be useful for this purpose. Drug release occurs through a combination of leaching 
of the active substance from the matrix and erosion of the matrix material. Another 
approach is to disperse the drug within an insoluble matrix. The most common 
insoluble matrix is one which is porous in nature, containing small channels and 
passages which are filled with drug. In vivo, fluids from the gastrointestinal tract 
penetrate and dissolve the drug, and the dissolved molecules then diffuse from these 
passages out of the matrix. Drug release is thus delayed as the dissolved molecules 
have to diffuse through a network of capillaries between the compact polymer 
particles forming the matrix. The kinetics of release from such matrices have been 
well studied by Higuchi (1963). 
 
Thus, coating the drug particles or pellets with a barrier membrane is an effective 
means of controlling the drug release. The barrier coat can either be slowly soluble or 
insoluble in nature. In the former case, the pellets release their contents through 
erosion of the coat. A typical product utilizing this release mechanism may consist of 
a capsule containing numerous pellets coated to various thicknesses with some 
erodible material. Since the rate of erosion of the coat can be expected to be 
dependent on the coat thickness, such a product will yield a relatively continuous 
 6 
 
drug release. The ‘Spansule’ dosage form discussed earlier was based on this design 
(Blythe, 1956). A variation of this method is to coat the pellets with different coating 
materials of different dissolution or disintegration times, or successively coating a 
spherical pellet, in between which, is placed the active drug (Hermelin, 1957). A 
second mechanism whereby coated pellets release their medicaments is by diffusion 
of the drug through the intact coat. Following ingestion, moisture within the 
gastrointestinal tract penetrates the coat to dissolve the solid drug. The dissolved 
drug molecules then diffuse through the intact barrier membrane. The rate of drug 
release can be controlled by varying the nature and/or thickness of the coat or by 
altering its porosity by incorporating some water soluble materials into the coat to act 
as channeling agents. It is interesting to note that osmosis has recently been 
suggested as an important mechanism for the drug release from such systems 
(Zentner et al., 1985; Lindstedt et al., 1989; Ozturk et al., 1990; Lindstedt et al., 
1991).  
 
Formulations in which osmosis pumping is a major release mechanism was described 
by Theeuwes in 1975. In this approach, the osmotically active solid, namely the drug 
or dispersion thereof is surrounded by a rigid rate-controlling membrane which is 
semipermeable with respect to water. Uptake of water through the rigid membrane at 
a controlled rate will cause the device to deliver, via an orifice in the membrane, a 
volume of saturated drug solution equal to the volume of water imbibed. The rate of 
drug release is constant so long as excess solid remains within the device. Because 
the mechanism of this system is based on osmotic pressure, the system delivers drug 
at a rate that is essentially independent of stirring rate and the environmental pH. A 
commercial therapeutic system based on the above principle has been marketed by 
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Alza Corporation USA, under the name ‘OROS’, and its applications has recently 
been examined with oxprenolol (Bradbrook et al., 1985), metoprolol (Godbillon et 
al., 1985a) and nifedipine (Chung et al., 1987). Some clinical problems were 
encountered in its use with indomethacin, resulting in the withdrawal of the product, 
and this has been well reviewed by Bem et al. (1988). Davis et al. (1988) have also 
investigated the gastrointestinal transit properties of ‘Oros’ containing the drug 
oxprenolol. The rate of appearance of the drug in the systemic circulation in relation 
to the location of the dosage in the gut was examined.  
 
1.2 Matrix controlled release systems   
One of the most popular approaches in the design and development of oral controlled 
preparations is based on the matrix system because of its low cost and ease of 
fabrication (Lee, 1985). Matrix systems are also called monoliths, since the drug is 
homogeneously dispersed throughout a rate-controlling medium. Most of the oral 
matrix controlled release products utilize either hydrophilic or hydrophobic matrix 
systems where the drug is uniformly dissolved or dispersed throughout the polymer 
mass (Khan and Reddy, 1997; Viega et al., 1997; 1998; Reza et al., 2003). The 
release mechanism of drug occurs mainly through diffusion and erosion. It is 
necessary to understand the material properties of the devices in order to predict the 
kinetics of drug release. A simple semi-empirical equation 1.1 shown below was put 
forward to describe the drug release behavior from a hydrophilic matrix system 
(Peppas, 1985; Ford et al., 1991) while the release from a hydrophobic monolithic 
matrix system that resulted in the square-root of time release profile has been 
described by Higuchi, 1963 in equation 1.2 below. 
 
Qt / Q∞ = Ktn                                                                            Eq (1.1) 
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Where, Qt / Q∞ is the fraction of drug releases at time t, K is the Korsmeyer-Peppas 
kinetic release constant which comprises the structural and geometric characteristics 
of the tablet, and n, is the release exponent, indicative of a parameter which depends 
on the drug release mechanism. 
 
This equation deals with diffusion and erosion mechanism of drug release, depending 
on the n value in the equation. If the n value is equal to or less than 0.45 this suggests 
that the release from the optimized formulations follows Fickian diffusion release 
mechanism (Case I diffusion) of drug where the relative relaxation time of the 
polymer is much shorter than the characteristic diffusion time of water transport 
which is controlled by concentration gradient. When, the n value is between 0.45 and 
0.89, it is considered to be non-Fickian type of release (Anomalous transport) which 
refers to a combination of both diffusion and erosion drug release mechanisms. On 
the other hand, when n value is equal to 0.89, the corresponds to zero-order kinetics 
(Case II), where polymer relaxation is the rate limiting step to the water transport and 
the time independent of diffusion. Finally when n value is greater than 0.89 the 
release is often referred to as a super case II. Generally, Case II transport refers to the 
dissolution of the polymeric matrix due to the relaxation of polymeric chains.   
 
Qt = KH t1/2                                                        Eq (1.2) 
 
Where Qt is the cumulative amount of drug released in time t, and KH is the Higuchi 
rate constant which represents the diffusion rate constant. This equation describes the 
drug release from systems where the solid drug is dispersed in an insoluble matrix, 
and the rate of drug release is related to the rate of drug diffusion. 
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Hydrophilic matrix consists of materials that swell and form gels upon contact with 
water or dissolution medium. Drug release in such system is controlled by the 
diffusion/leaching of the active substances through the swollen and hydrated matrix, 
as well as due to the erosion of the gelled layer (Peppas et al., 1985). Hydrogel is an 
important class of the hydrophilic matrix former, which is capable of swelling in 
water and retaining a considerable amount of water without dissolving in it (Breimer 
et al., 1985). The drug release follows Fickian first-order diffusion under equilibrium 
conditions. However, during the swelling process, such equilibrium may not exist 
and the diffusion may be non-Fickian or anomalous diffusion. 
 
1.3 Types of matrix systems 
 
As mentioned previously, the matrix systems can be mainly divided into two 
categories depending on whether the polymeric materials used to construct the 
matrices are hydrophilic or hydrophobic. 
 
1.3.1 Hydrophilic matrix systems 
Hydrophilic matrix systems are constructed using water soluble polymeric materials. 
When the water is thermodynamically compatible with a polymer, it penetrates into 
the free spaces between macromolecular chains of the polymers. The polymers may 
undergo a relaxation process, due to the stress of the penetrated solvent, so that the 
polymer chains become more flexible and the matrix swells (Rajabi-Siahboomi et al., 
1994a; 1994b; Rajabi-Siahboomi and Jordan, 2000). This allows the encapsulated 
drug to dissolve and diffuse out of the matrix. Drug release from the matrix is slowed 
since the diffusion path is lengthened by matrix swelling. However, polymer 
swelling and diffusion are not the only factors that determine the rate of drug release 
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(Sujja-Areevath et al., 1998). For dissolvable polymer matrix, polymer dissolution is 
another important mechanism that can modulate the drug release rate. While either 
swelling or dissolution can be the predominant factor for a specific type of polymer, 
in most cases drug release kinetic is a result of a combination of these two 
mechanisms (Tahara et al., 1995). Hydroxypropyl methylcellulose (HPMC) is one of 
the classical examples of water soluble matrix former. The presence of water 
decreases the glassy rubbery temperature for HPMC from 184°C to below 37°C, 
giving rise to transformation of glassy polymer to rubbery phase (gel layer). The 
enhanced motility of the polymeric chain favors the transport of dissolved drug and 
the polymer relaxation phenomenon determines the swelling or volume increase of 
the matrix. Depending on the polymer characteristics, the polymer amount in the 
rubbery phase on the surface of the matrix could reach a disentanglement 
concentration leading to an erosion of the matrix. The concentration at which 
polymeric chains can be considered disentangled was demonstrated to correspond to 
an abrupt change in the rheological properties of the gel. Boniferoni et al. (1995) 
showed a relationship between rheological behaviors of HPMC gels and their erosion 
rate, confirming that the polymer-polymer and polymer-water interaction are 
responsible for the gel network structure and its sensitivity to erosion. In turn, they 
affect drug release rate in the case of poorly soluble drugs Lee and Peppas (1987).  
 
Drug release from swellable matrix tablets can be affected by glassy rubbery 
transition of polymer (as a result of water penetration into the matrix where 
interaction among water, polymer and drug or fillers is considered as the primary 
factor for release control) and the various formulation variables, such as polymer 
grade and type, drug to polymer ratio, drug solubility, drug and polymer particle size, 
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compaction pressure and presence of additives or excipients in the final formulation. 
Lotfipour et al. (2004) investigated the effect of various polymers, fillers and their 
concentration on the release rate of atenolol form polymeric matrix. They concluded 
that the release rate and mechanism of atenolol release from hydrophobic and 
hydrophilic matrices are mainly controlled by the drug to polymer ratio. The results 
also showed that an increase in the concentration of fillers resulted in an increase in 
the release rate of the drug from matrices and hydrophilicity or hydrophobicity of the 
fillers had no significant effect on the release profile. Regarding the mechanism of 
release, the results showed that in most cases the drug release was controlled by both 
diffusion and erosion depending on the polymer type and concentration. On the other 
hand, incorporation of water soluble fillers like polyethylene glycol, lactose and 
surfactant into gel forming matrices can improve the drug release in case of matrices 
where complete drug is not released or is very slowly released, because these 
excipients can enhance the penetration of the solvent or water into the inner part of 
matrices (Genc et al., 1999; Nokhodchi et al., 2002).  
 
Polymers used in hydrophilic matrices  
Hydrophilic polymers were much investigated on the basis of drug release and 
release mechanism from hydrophilic matrix tablets as well as pellets (Alderman, 
1984; Khan et al., 1996; Khan and Jiabi, 1998; Khan and Zhu, 1998; Sen et al., 
2001; Huang et al., 2004). HPMC and HPC polymers achieve considerable attention, 
due to their unique properties along with their good compression characteristics. 
They are nontoxic and can accommodate high level of drug loading and also have 
adequate swelling properties that allow rapid formation of an external gel layer 
which retards or plays a major role in controlling the drug release (Carstensen et al., 
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1980; Carstensen, 1984; 1987; 1997; Mockel and Lippold, 1993; Swarbrick, 1996; 
Carstensen, 2000; Rani and Mishra, 2001; Mishra et al., 2003; 2005). Furthermore, 
HPMC polymers retard the drug release independent of the pH of the media. This 
advantage enables them to withstand fluctuations of pH in the gastrointestinal tract. 
They have been used alone or in combination with other hydrophilic polymers in the 
formulation of matrix tablets. Hence, hydrophilic gel forming matrix tablets have 
been extensively used for oral extended release dosage forms due to their simplicity, 
cost effectiveness and reduced risk of dose dumping which can lead to drug toxicity 
(Sung et al., 1996; Huang et al., 2004). Suleiman et al. (1989) investigated the 
release of diclofenac sodium from a mixture of HPMC and Carbopol 940 with 
lactose as the water soluble filler. The results showed that the combination of 
hydrogels retarded the drug better than using a single polymer. 
 
Hydroxypropyl methylcellulose (HPMC) is a water soluble hydrophilic polymer, 
with the ability to swell in water to form a swollen gel phase (Harland et al., 1988; 
Bonferoni et al., 1994). It is prepared by reacting alkali treated cellulose first with 
methyl chloride to introduce methoxy groups and then with propylene oxide to 
introduce propylene glycol ether groups. The resulting products are commercially 
available in different viscosity grades. The erosion of the gel layer is dependent on 
the polymer viscosity. Increasing viscosity yields slower drug release as a stronger, 
more viscous gel layer is formed, providing a greater barrier to diffusion and slower 
attrition of the tablets (Cheong et al., 1992). HPMC matrices undergo the following 
during dissolution test: absorption of dissolution media, swelling, gelling, erosion 
and complete dissolution at the end of test. The mechanism of release from hydrogel 
matrix systems is complex and has not been completely understood. In general, on 
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contact with aqueous medium, initially HPMC undergoes a relaxational process that 
is observed macroscopically as gelation and swelling (Vueba et al., 2004). As a 
result of these processes, a transparent gel layer appears. Outside this layer, there is 
an eroding front (gel/dissolution medium interface) at which HPMC chain 
disentanglement and concomitant dissolution of gel occurs. Inside this layer, there is 
a swelling front (glassy polymer/gel interface), at which HPMC hydrates, and swells. 
 
Huang et al. (2004) developed once daily propranolol extended release tablets using 
HPMC polymer as a retarding agent. The mechanism of the drug release from the 
HPMC matrix tablets followed non-Fickian diffusion, while the in vivo absorption 
and in vitro dissolution showed a linear relationship. 
 
Other polymers used in hydrophilic matrix preparations include poly ethylene oxide 
(Sriwongjanya and Bodmeier, 1998; Maggi et al., 2003), hydroxypropylcellulose 
(Ferrero et al., 1997) and hydroxyethylcellulose. 
 
Hydroxypropylcellulose (HPC) is non-ionic water-soluble cellulose ether, formed by 
reacting cellulose with propylene oxide. It provides a remarkable set of physical 
properties for tablet binding, sustained release and film coating (Veiga et al., 1997). 
It is soluble both in organic solvent as well as in water. Thermoplasticity and surface 
activity with aqueous thickening and stabilizing properties are the other 
characteristics of this polymer. It has a long standing history of safe and effective use 
in the pharmaceutical industry. The pharmaceutical grades of HPC (Klucel®) comply 
with the monograph requirements of the National Formulary, the European 
Pharmacopoeia, and the Japanese Pharmacopoeia.  
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Hydroxyethylcellulose (HEC) is non-ionic water-soluble cellulose ether, formed by 
reacting cellulose with ethylene oxide. It is used as a sustained release tablet matrix 
forming material, film former, thickener, stabilizer and suspending agent for oral and 
topical applications when a non-ionic material is desired (Veiga et al., 1998). HEC is 
easily dispersed in cold or hot water to give solutions of varying viscosities and 
desired properties. The pharmaceutical grades of HEC (Natrosol®) comply with the 
monograph requirements of the National Formulary and the European 
Pharmacopoeia. 
 
Xanthan gum (XG) is widely used as a thickening agent in food industries but 
recently introduced in pharmaceutical formulations (Talukdar and Kinget, 1995; 
Ntawaukulilyayo et al., 1996; Talukdar et al., 1996; Tobyn et al., 1996; Talukdar and 
Kinget, 1997; Talukdar et al., 1998; Santos et al., 2004; 2005; Veiga-Santos et al., 
2005). It is a high molecular weight extracellular heteropolysaccharide, produced by 
fermentation with the gram-negative bacterium Xanthamonas campestris. XG shows 
excellent swelling properties and the swelling of the XG polymer matrix shows a 
square root of time dependence whereas drug release is enentially linear (Talukdar 
and Kinget, 1995).  
 
Carbopol is a derivative of polyacrylic acid. It is a synthetic, high molecular weight, 
crosslinked polymer. It readily hydrates, absorbs water and swells making it a 
potential candidate for controlled release drug delivery systems (Khan and Jiabi, 
1998; Goskonda et al., 1998; Wong et al., 1999; Juang and storey, 2003; Ikinci et al., 
2004; Tapia-Albarran and Villafuerte-Robles, 2004). In the case of tablets 
formulated with Carbopol the drug is entrapped in the glassy rubbery core in the dry 
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state. It forms a gelatinous layer upon hydration. However, this gelatinous layer is 
significantly different structurally from the traditional matrix tablets. The hydrogel is 
not entangled chains of polymer, but discrete microgel made up of many polymer 
particles in which the drug is dispersed. The crosslinked network enables the 
entrapment of drug in the hydrogel domains. Since these hydrogels are not water 
soluble, they do not dissolve and erode. Rather, when the hydrogel is fully hydrated, 
osmotic pressure from within works to break up the structure, essentially by 
sloughing off discrete pieces of the hydrogel. This hydrogel remains intact and the 
drug continues to diffuse through the gel layer at a uniform rate (Khan and Jiabi, 
1998). 
 
It is well recognized that the key formulation variables are matrix dimension and 
shape, polymer level and molecular weight, as well as drug loading and solubility. 
Other factors such as tablet hardness, type of inactive ingredients and processing 
normally play secondary roles. The choice of manufacturing process such as direct 
blending or granulation typically does not affect product performance significantly, 
although exception does exist. In general, processing and scale up associating with 
hydrophilic matrices are more robust than other controlled release systems 
(Upadrashta et al., 1993; Velasco et al., 1999; Venkatraman et al., 2000; Soliman et 
al., 2005).  
 
1.3.2 Hydrophobic matrix systems 
 
Hydrophobic matrix systems are constructed using water insoluble polymeric 
materials. The hydrophobic matrix formers include waxes (Vergote et al., 2001; 
Hayashi et al., 2005), glycerides (Yuksel et al., 2003), fatty acids and polymeric 
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materials such as ethyl cellulose (Crowley et al., 2004) and acrylate copolymer 
(Azarmi et al., 2002; Krajacic and Tucker, 2003). To modulate drug release, it may 
be necessary to incorporate soluble ingredients such as lactose into the formulations. 
The presence of insoluble ingredient in the formulations helps to maintain the 
physical integrity of the hydrophobic matrix during drug release. As such, diffusion 
of active ingredients from the system is the release mechanism (Kincl et al., 2004) 
and the corresponding release characteristics can be described by Higuchi equation 
known as square root of time release kinetics (Higuchi, 1963). The square root of 
time release profile is expected with a porous monolith, where the release from such 
system is proportional to the drug loading. In general, hydrophobic matrix systems 
are not suitable for water insoluble drugs because the concentration gradient is too 
low to render adequate drug release. As such, depending on actual ingredient 
properties or formulation design, incomplete drug release within the gastrointestinal 
transit time is a potential risk and need to be delineated during the developmental 
stages. 
 
Polymers used in hydrophobic matrices  
Ethylcellulose is one of the most widely used water insoluble hydrophobic polymer. 
It can be applied either as an organic solution or as an aqueous colloidal dispersion. 
Ethylcellulose is essentially tasteless, odorless, colorless, noncaloric and 
physiologically inert (Donbrow and Friedman, 1974; Spited and Kinget, 1980; Iyer et 
al., 1990). Ethylcellulose contains 44 to 51% of ethoxy groups manufactured by 
reacting ethyl chloride or ethyl sulfate with cellulose dissolved in hydroxide. 
Depending on the degree of ethoxy substitution, different viscosity grades are 
obtained and available. This material is completely insoluble in water and 
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gastrointestinal fluids, and thus cannot be used alone for tablet coating. It is usually 
combined with water soluble additives, such as hydroxypropyl methylcellulose, to 
prepare films with reduced water solubility properties (Lachman et al., 1986; 
Sadeghi et al., 2000).  
 
Kollidon® SR is a newly developed sustained release matrix excipient based on a 
mixture of polyvinyl acetate and povidone. Due to its excellent flow and 
compression properties, it is highly suitable for tablets made by direct compression 
(Draganoiu et al., 2001). Polyvinyl acetate is a very plastic material that produces a 
coherent matrix even under low compression forces. When the tablets are introduced 
into dissolution media, the water soluble povidone is leached out to form pores 
through which the active ingredient slowly diffuses outwards.   
 
1.4 Advantages and disadvantages of oral controlled release dosage forms  
 
1.4.1 Advantages 
 
Oral controlled release dosage forms offer great advantages due to better therapeutic 
success than with conventional dosage forms of the same drug (Reza et al., 2003). 
The advantages include (1) remarkable decrease in dosing frequency and improved 
patient compliance, (2) minimized in vivo fluctuation of drug concentrations and 
maintenance of drug concentrations within a desired range (Urquhart, 1982), (3) 
reduced side effects, and (4) reduction in health care costs through improved therapy, 
shorter treatment period, less frequency of dosing and reduction in personnel time to 
dispense, administer and monitor patients.  
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This is of great importance, especially for drugs used in long term treatment of 
chronic diseases. Moreover, controlled release dosage forms are useful for delivering 
drugs with narrow therapeutic indices since they can reduce the peak trough 
fluctuations in blood concentration, being characteristic of multiple dosing using 
conventional immediate release dosage forms (George et al., 1978; Longer and 
Robinson, 1990). A better efficacy and toxicity ratio of drug during the complete 
dosing interval could be obtained. Large fluctuations in the blood levels may produce 
high peak drug levels associated with toxicity while low trough levels result in the 
loss of efficacy. Hence, a better disease management and reliable therapy can be 
achieved with the controlled release dosage forms (Chaffman and Brogden, 1985).  
 
1.4.2 Disadvantages 
Oral controlled release dosage forms also suffer from a number of potential 
disadvantages which generally include (1) higher cost, (2) reduced bioavailability, 
(3) possible dose dumping, (4) reduced potential for dose change or withdrawal in 
the event of toxicity, allergy or poisoning, and (5) increased first pass metabolism for 
certain drugs. Unpredictable and poor in vitro/in vivo correlations and bioavailability 
are often observed with such formulations, especially when the drug release rate is 
very low or drug absorption from the colon is involved. Dose dumping is a 
phenomenon where a large amount of the drug is released from a controlled release 
formulation in a short period of time, resulting in undesired high plasma drug levels 
and potential toxicity. Basically, this can occur due to a breakdown of the rate 
controlling mechanism, such as rapid disintegration of the matrix tablet. 
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1.5 Tableting 
Tablets are solid pharmaceutical unit dosage forms containing medicinal substances 
with or without suitable diluents and prepared either by molding or by compression 
methods. They vary greatly in shape, size and weight which depend upon the amount 
of medicinal substances and the mode of administration. 
 
Most commonly, tablets are disk shaped with convex surfaces but they are also 
available in special shapes like round, oval, oblong, cylindrical, square, triangular 
etc. they can also vary greatly in weight. Tablets are the most widely used solid 
dosage form of medicament because they offer a number of advantages to the 
patient, prescriber, manufacturer and the manufacturing pharmacist (Chien, 1978; 
Chien, 1983; Patel and Amiji, 1996; Streubel et al., 2000; 2006). 
 
Tableted drug delivery systems can range from relatively simple immediate release 
formulations to complex extended or modified release dosage forms. The role of an 
oral drug delivery system is to deliver the drug in sufficient amount and at 
appropriate rate at the site of absorption. However, it must also meet a number of 
other essential criteria. These include physical and chemical stability, ability to 
economically mass produce and patient acceptability (Augsburger and Zellhofer, 
2002). 
 
Tablets are prepared by compressing a powder mixture in a die at high compression 
force. Generally, the powder mixture contains diluents, binders, disintegrants, 
lubricants and glidants, apart from the active ingredient. In large scale production of 
high quality tablets, a tablet mixture with excellent homogeneity, flowability and 
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compatibility properties is required. Granulation imparts good compactibility, and 
flowability, which is most commonly used in production of high quality tablets. The 
two methods used in granulation process are dry granulation and wet granulation.  
 
In dry granulation, the dry powder particles may be brought together mechanically 
via compression to form slugs, or more frequently via compaction by a roller 
compactor. This method has been utilized when one of the constituents, either the 
drug or the excipients has insufficient cohesive or flow properties to be directly 
compressed into tablets. Dry granulation is a valuable technique in situations where 
the effective dose of drug is too high for direct compression and the drug is sensitive 
to heat, moisture or both, which precludes wet granulation (Banaker, 1979; 1991). 
 
With wet granulation, extra process steps are necessary to produce a tablet mass with 
sufficient tableting properties. After dry blending the tablet mixture to uniformity, a 
binder solution is added to the mixture to moisten the particles. Introduction of the 
binder solution improves binding between the particles and therefore can produce 
stronger tablets. Mixing is continued until granules with a specific diameter are 
produced. This wet mass is then screened to remove large lumps, and dried in oven 
to remove granulation fluid. Finally, the granules are sieved to remove the 
agglomerates that are formed during drying followed by lubrication of the granules.  
 
The other technique for tablet production is direct compression. In direct 
compression, the powder mixture is blended to form a uniform mixture and is 
directly compressed into tablets without any modification of its physical nature. 
Lubrication step may be necessary to prevent the mixture from adhesing to the die 
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and punches during compression. Tablet mixtures having good flow and binding 
properties during compaction are suitable for direct compression (Kristensen et al., 
1993).  
 
1.6 Influence of physiological conditions on performance of oral controlled 
release dosage forms 
 
The human gastrointestinal tract can be divided into following major sections, 
namely, the stomach, the small intestine, and the colon. These sections differ in both 
anatomical and physiological characteristics. 
 
The stomach is mainly responsible for storage and mixing. Its fundus and body are 
capable of large expansion to accommodate food without much increase in the 
intragastric pressure, whilst the antrum, is responsible for mixing and grinding of 
gastric contents. At resting/fasting state, the pH of stomach is acidic with a value of 1 
to 3 (Youngberg et al., 1987). Gastric absorption of most drugs is insignificant due to 
its limited surface area of 0.1 to 0.2 m2 (Chien, 1992). The stomach is always in a 
state of continuous motility, and there are two modes of motility patterns, namely, 
the digestive and the inter-digestive modes (Quigley et al., 1984). The inter-digestive 
mode is characterized by a cyclic pattern that originates in the foregut and propagates 
to the terminal ileum. The cyclic pattern consists of four distinct phases known as 
phase I, representing an inactive period with no electrical activity and no contraction, 
phase II, the period of random spike activity or intermittent contractions, phase III, 
the period of regular spike bursts or regular contractions at the maximal frequency 
that migrate distally, which is also known as “housekeeper wave”, as it plays a 
housekeeping role in clearing all indigestible materials from the stomach, and finally, 
phase IV, the transition period between phase III and phase I. The average length of 
 22 
 
one complete cycle of these four phases is known as the interdigestive migrating 
motor complex (MCC) and has an average duration of 90 to 120 min (McRae et al., 
1982; Chien, 1992). 
 
On the other hand, the pH of the small intestine is about 4 to 7, increasing from the 
proximal to the distal region. Because of the presence of vast number of villi and 
microvillus on its mucosal surface, a huge absorptive area of between 200 to 500 m2 
(Davenport, 1977) is presented. Therefore the small intestine is the major region for 
drug absorption. The number of villi is most numerous in the duodenum and 
proximal jejunum. There is a progressive decrease in surface area from the proximal 
to the distal region of the small intestine and colon. As a result, the proximal region 
of the small intestine may be regarded as the most efficient absorption site. Hence, in 
order to achieve maximum systemic bioavailability, the drug should be targeted for 
delivery in the locality of this region. 
 
In the case of colon, the most important function is to store indigestible food 
residues. The luminal content of the colon is much more viscous than in the small 
intestine, with a high pH of about 7.4 or can be higher up to 8. Due to its small 
absorptive area, as well as lack of villi there is reduced drug absorption as compared 
to the small intestine. In general, colonic drug absorption is incomplete and variable 
(Koch-Weser and Schechter, 1981). In the distal part of the colon, insignificant drug 
absorption is mainly attributed to the embedding of remaining drug in semisolid 
faecal matter (Hirtz, 1984). 
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The small intestinal transit time for both liquids and solids, regardless of their nature, 
normally takes three to four hours,  and unaffected by food (Cammack et al., 1982; 
Davis et al., 1984b, 1987; Devereux, 1987; Ollerenshaw et al., 1987; Mundy et al., 
1989). In contrast, gastric emptying is highly variable and is markedly influenced by 
diet (Hunt and Knox, 1968; Cooke and Moulang, 1972; Christian et al., 1980; Davis 
et al., 1984b; Moore et al., 1981; Davis et al., 1987; Devereux, 1987). 
 
1.7 Evaluations of controlled release dosage forms 
 
1.7.1 In vitro evaluation 
The dissolution rate of a drug has a great influence on its absorption/bio-availability. 
The best method of evaluating the bioavailability of a dosage form is to perform in 
vivo study using human volunteers. However, monitoring batch to batch consistency 
through use of such in vivo test is extremely costly, tedious and time consuming. It 
would therefore be always desirable to substitute the in vivo bio-availability tests 
with inexpensive in vitro methods (Brahmankar et al., 2000). 
 
In vitro dissolution study is valuable in the initial stages of development and 
evaluation of controlled release dosage forms. It also provides useful information 
regarding the factors that could affect the drug release from the controlled release 
preparations. The factors include processing variables, batch to batch uniformity as 
well as alterations in formulation and stability determinations during various stages 
of the development process. Furthermore, it can also be employed as a replacement 
for evaluation of bioequivalence under certain conditions. In view of the significance 
of dissolution, it is therefore essential to investigate the drug release characteristics of 
preparations. 
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1.7.1 (a) In vitro dissolution apparatus 
 
A high-quality dissolution test system possesses certain attributes. Firstly, the results 
must be reproducible and associated with some characteristics of the in vivo data. 
Secondly, the test must be sufficiently sensitive to differentiate in vitro variables that 
yield in vivo differences, but without being overly sensitive in detecting in vitro 
changes that is negligible in vivo. Thirdly, the method should be flexible and 
applicable to a wide range of products and lastly, the system should be amenable to 
automation (Smollen and Ball, 1984).  
 
A wide range of dissolution testing devices has been successfully developed and 
reviewed (Banaker, 1991). They are basically similar in principle, although the 
procedures involved may differ. Generally, the dissolution systems can be classified 
into two distinct types, the stirred vessels and the flow through column systems. The 
former contains relatively large volume of dissolution medium with minimal liquid 
exchange. Agitation is achieved either by stirring the liquid with a rotating blade or 
motion of the vessel itself. The second type comprises a small dissolution cell 
through which fresh solvent flows at a constant rate without any agitation. The USP 
28 (2005) dissolution testing methods for oral dosage forms include the basket 
stirring element (apparatus 1), paddle stirring element (apparatus 2), reciprocating 
cylinders system (apparatus 3), flow through cell system (apparatus 4), paddle over 
disk (apparatus 5), cylinder (apparatus 6) and reciprocating holder (apparatus 7). 
These methods are easy to operate and amenable to automation. Other systems 
include the rotating bottle, stationary basket, rotating filter, Sartorius absorption and 
solubility and column type flow through assembly (Lordi, 1986). 
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It is impracticable to simulate all the variables that affect the drug dissolution in the 
gastro-intestinal tract in a single in vitro dissolution test system. However, regardless 
of the types of dissolution test system, certain process variables are essential to 
obtain meaningful results, and should be included in the dissolution test methodology 
(Smollen and Ball, 1984). An agitation rate capable of discriminating in vitro 
conditions that are important in vivo should be sought, bearing in mind that agitation 
in the gastrointestinal tract under normal condition is mild (Gupta and Robinson, 
1992). The normal body temperature of 37º C is a desired feature in dissolution 
apparatuses. In this regards, an allowance of ± 0.5º C is deemed acceptable. The 
dissolution medium may be buffered at different pH to simulate the changes in pH 
along the gastrointestinal tract. This may help to determine the dependence of drug 
release at various sections of the gastrointestinal tract. 
 
1.7.1 (b) Comparison of In vitro dissolution profiles 
 
The United State Food and Drug Administration guidance for industry (USFDA, 
2003) on dissolution testing of solid oral dosage forms, offers general 
recommendations for dissolution testing, approaches for site dissolution 
specifications related to the biopharmaceutical characteristics of the drug material, 
statistical methods for comparing dissolution profiles, and a process to help 
determine when dissolution testing is sufficient to grant a waiver for an in vivo bio-
equivalence study.  
 
Shah et al. (1987) applied a multivariate analysis of variance method to test the 
difference between two dissolution profiles. Tsong et al. (1996) proposed dissolution 
difference measurement and similarity testing based on multivariate distance 
